Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Keeps “Buy” Rating at Needham & Company LLC

Recursion Pharmaceuticals (NASDAQ:RXRX)‘s stock had its “buy” rating reiterated by research analysts at Needham & Company LLC in a report released on Monday, Benzinga reports. They currently have a $8.00 price target on the stock. Needham & Company LLC’s price objective indicates a potential upside of 126.76% from the company’s previous close.

RXRX has been the subject of several other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Thursday. Morgan Stanley set a $5.90 target price on Recursion Pharmaceuticals in a research report on Friday. Finally, Wall Street Zen raised Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $8.18.

Recursion Pharmaceuticals Stock Performance

NASDAQ:RXRX opened at $3.53 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.03 and a quick ratio of 5.03. The firm has a market capitalization of $1.89 billion, a price-to-earnings ratio of -3.38 and a beta of 1.04. The company’s 50-day moving average is $3.64 and its two-hundred day moving average is $3.42. Recursion Pharmaceuticals has a 1-year low of $2.77 and a 1-year high of $6.70.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%. The firm had revenue of $7.67 million for the quarter, compared to analyst estimates of $10.97 million. During the same quarter in the prior year, the business earned ($0.41) EPS. Analysts forecast that Recursion Pharmaceuticals will post -0.94 EPS for the current year.

Insider Activity

In other news, CEO Najat Khan sold 22,408 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $3.52, for a total value of $78,876.16. Following the completion of the transaction, the chief executive officer owned 2,072,890 shares of the company’s stock, valued at approximately $7,296,572.80. This trade represents a 1.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert Hershberg sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $5.00, for a total transaction of $125,000.00. Following the sale, the director directly owned 162,156 shares in the company, valued at approximately $810,780. The trade was a 13.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 157,408 shares of company stock valued at $643,576. 6.65% of the stock is currently owned by company insiders.

Institutional Trading of Recursion Pharmaceuticals

A number of large investors have recently modified their holdings of the stock. Ascent Wealth Partners LLC boosted its stake in shares of Recursion Pharmaceuticals by 11.8% during the 1st quarter. Ascent Wealth Partners LLC now owns 28,081 shares of the company’s stock worth $86,000 after acquiring an additional 2,974 shares in the last quarter. Cherry Creek Investment Advisors Inc. increased its stake in Recursion Pharmaceuticals by 5.8% in the 1st quarter. Cherry Creek Investment Advisors Inc. now owns 70,536 shares of the company’s stock valued at $217,000 after purchasing an additional 3,859 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in Recursion Pharmaceuticals by 33.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 16,832 shares of the company’s stock valued at $52,000 after purchasing an additional 4,199 shares in the last quarter. Sequoia Financial Advisors LLC raised its holdings in Recursion Pharmaceuticals by 51.5% during the first quarter. Sequoia Financial Advisors LLC now owns 15,162 shares of the company’s stock worth $47,000 after purchasing an additional 5,156 shares during the last quarter. Finally, Axxcess Wealth Management LLC raised its holdings in Recursion Pharmaceuticals by 16.6% during the first quarter. Axxcess Wealth Management LLC now owns 37,516 shares of the company’s stock worth $115,000 after purchasing an additional 5,338 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc is a clinical-stage biotechnology company that uses biology, chemistry, automation and machine learning to discover and develop new medicines. The company’s technology platform is designed to generate and analyze large volumes of biological and chemical data, helping researchers identify potential drug candidates and better understand disease mechanisms.

Recursion has focused its research and development activities on areas including oncology, rare diseases and neuroscience.